Diversity in antibody-based approaches to non-Hodgkin lymphoma
(2010) 7th International Workshop on Non-Hodgkins Lymphoma 51. p.20-27- Abstract
- Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and... (More)
- Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and in some cases have demonstrated improved efficacy over currently available treatments. Radioimmunotherapy has been included in transplant conditioning regimens to improve long-term disease control while limiting toxicity. These regimens have been safe, effective, and feasible, and are therefore promising for patients who cannot tolerate high-dose chemotherapy and/or total body irradiation. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1694782
- author
- Maloney, David ; Morschhauser, Franck ; Lindén, Ola LU ; Hagenbeek, Anton and Gisselbrecht, Christian
- organization
- publishing date
- 2010
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- monoclonal, Non-Hodgkin lymphoma, CD20, B cells, antibodies
- host publication
- Leukemia & Lymphoma
- volume
- 51
- pages
- 20 - 27
- publisher
- Taylor & Francis
- conference name
- 7th International Workshop on Non-Hodgkins Lymphoma
- conference dates
- 2009-10-02 - 2009-10-03
- external identifiers
-
- wos:000282233100003
- scopus:77956445009
- pmid:20815760
- ISSN
- 1042-8194
- DOI
- 10.3109/10428194.2010.500047
- language
- English
- LU publication?
- yes
- id
- b9c7aac7-3b51-4e58-8ae5-b6110855187f (old id 1694782)
- date added to LUP
- 2016-04-01 14:30:39
- date last changed
- 2022-01-28 00:57:28
@inproceedings{b9c7aac7-3b51-4e58-8ae5-b6110855187f,
abstract = {{Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for similar to 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that t arget CD20 antigens on the surface of malignant tumors. The use of mAbs, either as single agents or in combination with chemotherapy, has made a huge impact on NHL survival rates. Rituximab remains the most commonly used and established mAb, and is used in a wide range of NHLs, but does not produce an effective therapeutic response in all patients. Novel therapeutics with enhanced binding affinity or alternative antigen targets are currently in development and in some cases have demonstrated improved efficacy over currently available treatments. Radioimmunotherapy has been included in transplant conditioning regimens to improve long-term disease control while limiting toxicity. These regimens have been safe, effective, and feasible, and are therefore promising for patients who cannot tolerate high-dose chemotherapy and/or total body irradiation.}},
author = {{Maloney, David and Morschhauser, Franck and Lindén, Ola and Hagenbeek, Anton and Gisselbrecht, Christian}},
booktitle = {{Leukemia & Lymphoma}},
issn = {{1042-8194}},
keywords = {{monoclonal; Non-Hodgkin lymphoma; CD20; B cells; antibodies}},
language = {{eng}},
pages = {{20--27}},
publisher = {{Taylor & Francis}},
title = {{Diversity in antibody-based approaches to non-Hodgkin lymphoma}},
url = {{http://dx.doi.org/10.3109/10428194.2010.500047}},
doi = {{10.3109/10428194.2010.500047}},
volume = {{51}},
year = {{2010}},
}